Genzyme, Isis complete license agreement for cholesterol drug


CAMBRIDGE, Mass. Genzyme and Isis Pharmaceuticals announced Tuesday that they had finished a license and collaboration agreement for mipomersen, a drug candidate designed for patients with high cholesterol.

Under the agreement, Genzyme will pay Isis $175 million in licensing fees. Isis will contribute up to $175 million for development. After that, the two companies will share development costs. Isis may also receive up to $1.5 billion in commercial, development and regulatory milestone payments. Genzyme will have preferred access to future drugs that Isis develops for rare diseases and diseases affecting the central nervous system.

The companies will share profits for the drug, with Genzyme receiving 70 percent and Isis receiving 30 percent. They will split profits equally once revenues on mipomersen reach $2 billion. Genzyme will also be responsible for funding sales and marketing until revenues can cover them.

“Mipomersen is an innovative treatment that has the potential to change the standard of care for severely ill patients whose needs cannot be addressed by current cholesterol-lowering therapies,” said Henri A. Termeer, Genzyme’s chairman and chief executive officer.

This ad will auto-close in 10 seconds